Published in Am J Gastroenterol on May 17, 2007
The changing epidemiology of Clostridium difficile infections. Clin Microbiol Rev (2010) 4.48
Invasive non-Typhi Salmonella disease in Africa. Clin Infect Dis (2009) 2.40
Safety of the long-term use of proton pump inhibitors. World J Gastroenterol (2010) 1.55
Depression, antidepressant medications, and risk of Clostridium difficile infection. BMC Med (2013) 1.54
Overutilization of proton-pump inhibitors: what the clinician needs to know. Therap Adv Gastroenterol (2012) 1.43
Proton pump inhibitors alter the composition of the gut microbiota. Gut (2015) 1.28
Reductions in intestinal Clostridiales precede the development of nosocomial Clostridium difficile infection. Microbiome (2013) 1.26
Inflammatory mediators in gastroesophageal reflux disease: impact on esophageal motility, fibrosis, and carcinogenesis. Am J Physiol Gastrointest Liver Physiol (2010) 1.20
Proton pump inhibitors and hospitalization with hypomagnesemia: a population-based case-control study. PLoS Med (2014) 1.20
The role of protein digestibility and antacids on food allergy outcomes. J Allergy Clin Immunol (2008) 1.19
Immune status, antibiotic medication and pH are associated with changes in the stomach fluid microbiota. ISME J (2013) 1.17
Proton pump inhibitors affect the gut microbiome. Gut (2015) 1.17
Importance of gastrin in the pathogenesis and treatment of gastric tumors. World J Gastroenterol (2009) 1.12
Association between proton pump inhibitor therapy and clostridium difficile infection: a contemporary systematic review and meta-analysis. PLoS One (2012) 1.08
Campylobacter epidemiology: a descriptive study reviewing 1 million cases in England and Wales between 1989 and 2011. BMJ Open (2012) 1.07
The occurrence and prevention of foodborne disease in vulnerable people. Foodborne Pathog Dis (2011) 1.06
Implication of gut microbiota in nonalcoholic fatty liver disease. PLoS Pathog (2015) 1.03
Gastric acid suppression and outcomes in Clostridium difficile infection: a population-based study. Mayo Clin Proc (2012) 1.02
Acid peptic diseases: pharmacological approach to treatment. Expert Rev Clin Pharmacol (2009) 1.00
Proton pump inhibitor use in the U.S. ambulatory setting, 2002-2009. PLoS One (2013) 0.98
Current trends in the management of gastroesophageal reflux disease: a review. ISRN Gastroenterol (2012) 0.95
The risks of PPI therapy. Nat Rev Gastroenterol Hepatol (2012) 0.94
The association between histamine 2 receptor antagonist use and Clostridium difficile infection: a systematic review and meta-analysis. PLoS One (2013) 0.94
Risk factors for complications and mortality of percutaneous endoscopic gastrostomy: a multicenter, retrospective study. Surg Endosc (2013) 0.93
Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppression. BMC Med (2016) 0.92
Variables associated with stress ulcer prophylaxis misuse: a retrospective analysis. Dig Dis Sci (2012) 0.91
Does PPI therapy predispose to Clostridium difficile infection? Nat Rev Gastroenterol Hepatol (2009) 0.91
Use of proton pump inhibitors and subsequent risk of celiac disease. Dig Liver Dis (2013) 0.91
Proton pump inhibitors increase the risk for hospital-acquired Clostridium difficile infection in critically ill patients. Crit Care (2014) 0.87
Use of proton-pump inhibitors and their associated risks among frail elderly nursing home residents. Scand J Prim Health Care (2010) 0.86
Mechanisms and therapeutic effectiveness of lactobacilli. J Clin Pathol (2015) 0.85
Trends in Clostridium difficile infection and risk factors for hospital acquisition of Clostridium difficile among children with cancer. J Pediatr (2013) 0.85
Review of medical and surgical management of Clostridium difficile infection. Tech Coloproctol (2010) 0.85
C. difficile Infection: Changing Epidemiology and Management Paradigms. Clin Transl Gastroenterol (2015) 0.85
Efficacy and safety of proton pump inhibitors for stress ulcer prophylaxis in critically ill patients: a systematic review and meta-analysis of randomized trials. Crit Care (2016) 0.84
Suboptimal prescribing of proton-pump inhibitors in low-dose aspirin users: a cohort study in primary care. BMJ Open (2013) 0.83
The safety of drugs used in acid-related disorders and functional gastrointestinal disorders. Gastroenterol Clin North Am (2010) 0.83
Probiotics for antibiotic-associated diarrhea: do we have a verdict? World J Gastroenterol (2014) 0.83
Inhibition of lysosomal enzyme activities by proton pump inhibitors. J Gastroenterol (2013) 0.82
Stress ulcer prophylaxis with a proton pump inhibitor versus placebo in critically ill patients (SUP-ICU trial): study protocol for a randomised controlled trial. Trials (2016) 0.81
Clinical update for the diagnosis and treatment of Clostridium difficile infection. World J Gastrointest Pharmacol Ther (2014) 0.81
Do proton pump inhibitors protect against cancer progression in GERD? Surg Today (2012) 0.81
The impact of proton-pump inhibitors on intraperitoneal sepsis: a word of caution for transgastric NOTES procedures. Surg Endosc (2009) 0.81
Association Between Use of Proton Pump Inhibitors and a Clostridium difficile-Associated Disease Outbreak: Case-Control Study. Can J Hosp Pharm (2010) 0.80
Association between proton pump inhibitor use and spontaneous bacterial peritonitis in cirrhotic patients with ascites. Can J Gastroenterol Hepatol (2014) 0.80
Education-based approach to addressing non-evidence-based practice in preventing NSAID-associated gastrointestinal complications. World J Gastroenterol (2009) 0.80
Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2015. J Gastroenterol (2016) 0.79
Acid suppression and the risk of Clostridium difficile infection. J Pediatr (2013) 0.79
Gastroesophageal reflux symptoms do not correlate with objective pH testing after peroral endoscopic myotomy. Surg Endosc (2015) 0.79
Proton pump inhibitor use before percutaneous endoscopic gastrostomy is associated with adverse outcomes. Gut Liver (2014) 0.77
Proton pump inhibitors and gastroenteritis. Eur J Epidemiol (2016) 0.77
Clostridium difficile infection in patients with liver disease: a review. Eur J Clin Microbiol Infect Dis (2015) 0.77
Clostridium difficile Infection and Proton Pump Inhibitor Use in Hospitalized Pediatric Cystic Fibrosis Patients. Gastroenterol Res Pract (2011) 0.76
Associations between medication use and functional gastrointestinal disorders: a population-based study. Neurogastroenterol Motil (2013) 0.76
Inhibition of Gastric Acid Secretion by H2 Receptor Antagonists Associates a Definite Risk of Enteric Peritonitis and Infectious Mortality in Patients Treated with Peritoneal Dialysis. PLoS One (2016) 0.76
Managing peptic ulcer and gastroesophageal reflux disease in elderly Chinese patients--focus on esomeprazole. Clin Interv Aging (2013) 0.76
History of antimicrobial use and the risk of Dientamoeba fragilis infection. Eur J Clin Microbiol Infect Dis (2015) 0.76
Effects of proton pump inhibitors and histamine-2 receptor antagonists on response to fidaxomicin or vancomycin in patients with Clostridium difficile-associated diarrhoea. BMJ Open Gastroenterol (2015) 0.76
Effect of Metronidazole in Infants with Bowel Habit Change: Irrelative to the Clostridium difficile Colonization. Pediatr Gastroenterol Hepatol Nutr (2017) 0.75
Potential harms of proton pump inhibitor therapy: rare adverse effects of commonly used drugs. CMAJ (2015) 0.75
Gastrointestinal tuberculosis is not associated with proton pump inhibitors: a retrospective cohort study. World J Gastroenterol (2013) 0.75
Enterosalivary nitrate metabolism and the microbiome: intersection of microbial metabolism, nitric oxide and diet in cardiac and pulmonary vascular health. Free Radic Biol Med (2016) 0.75
Proton Pump Inhibitors Interfere With Zinc Absorption and Zinc Body Stores. Gastroenterology Res (2011) 0.75
Acid suppression medications and bacterial gastroenteritis: a population-based cohort study. Br J Clin Pharmacol (2017) 0.75
Etiology and Risk Factors of Acute Gastroenteritis in a Taipei Emergency Department: Clinical Features for Bacterial Gastroenteritis. J Epidemiol (2015) 0.75
Proton Pump Inhibitor use in Hospitalized Patients: Is Overutilization Becoming a Problem? Clin Med Insights Gastroenterol (2012) 0.75
Prediction and prevention of upper gastrointestinal bleeding after cardiac surgery: a case control study. Can J Gastroenterol (2012) 0.75
The Safety of Appropriate Use of Over-the-Counter Proton Pump Inhibitors: An Evidence-Based Review and Delphi Consensus. Drugs (2017) 0.75
Balancing the risks and benefits of proton pump inhibitors. Ann Fam Med (2011) 0.75
Widespread use of gastric acid inhibitors in infants: Are they needed? Are they safe? World J Gastrointest Pharmacol Ther (2016) 0.75
The Association between GABA-Modulators and Clostridium difficile Infection - A Matched Retrospective Case-Control Study. PLoS One (2017) 0.75
Association of Gastric Acid Suppression With Recurrent Clostridium difficile Infection: A Systematic Review and Meta-analysis. JAMA Intern Med (2017) 0.75
Recent Advances in the Pharmacological Management of Gastroesophageal Reflux Disease. Dig Dis Sci (2017) 0.75
The Gastric and Intestinal Microbiome: Role of Proton Pump Inhibitors. Curr Gastroenterol Rep (2017) 0.75
Proton Pump Inhibitors in Gastroesophageal Reflux Disease: Friend or Foe. Curr Gastroenterol Rep (2017) 0.75
Proton-pump inhibitors: understanding the complications and risks. Nat Rev Gastroenterol Hepatol (2017) 0.75
Gastric Hyperplastic Polyps Associated with Proton Pump Inhibitor Use in a Case without a History of Helicobacter pylori Infection. Intern Med (2017) 0.75
Consensus recommendations for managing patients with nonvariceal upper gastrointestinal bleeding. Ann Intern Med (2003) 5.15
British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus. Gut (2013) 4.29
Detection of intestinal metaplasia in Barrett's esophagus: an observational comparator study suggests the need for a minimum of eight biopsies. Am J Gastroenterol (2007) 4.14
Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ (2008) 4.12
Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol (2011) 3.97
Genetic risk factors for post-infectious irritable bowel syndrome following a waterborne outbreak of gastroenteritis. Gastroenterology (2010) 3.32
Effect of comorbidity on mortality in patients with peptic ulcer bleeding: systematic review and meta-analysis. Am J Gastroenterol (2013) 2.97
Will the history and physical examination help establish that irritable bowel syndrome is causing this patient's lower gastrointestinal tract symptoms? JAMA (2008) 2.89
Consensus statements for management of Barrett's dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process. Gastroenterology (2012) 2.68
Diagnostic and therapeutic use of proton pump inhibitors in non-cardiac chest pain: a metaanalysis. Am J Gastroenterol (2005) 2.56
Optimum duration of regimens for Helicobacter pylori eradication. Cochrane Database Syst Rev (2013) 2.53
Management of Barrett's esophagus in the UK: overtreated and underbiopsied but improved by the introduction of a national randomized trial. Am J Gastroenterol (2008) 2.52
Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding. Cochrane Database Syst Rev (2010) 2.47
Limited value of alarm features in the diagnosis of upper gastrointestinal malignancy: systematic review and meta-analysis. Gastroenterology (2006) 2.46
American gastroenterological association technical review on the evaluation of dyspepsia. Gastroenterology (2005) 2.39
Canadian Consensus Conference on the management of gastroesophageal reflux disease in adults - update 2004. Can J Gastroenterol (2005) 2.36
Minimizing postcolonoscopy abdominal pain by using CO(2) insufflation: a prospective, randomized, double blind, controlled trial evaluating a new commercially available CO(2) delivery system. Gastrointest Endosc (2002) 2.24
Eight year prognosis of postinfectious irritable bowel syndrome following waterborne bacterial dysentery. Gut (2010) 2.21
Validation of the Rome III criteria for the diagnosis of irritable bowel syndrome in secondary care. Gastroenterology (2013) 2.13
Helicobacter pylori "test and treat" or endoscopy for managing dyspepsia: an individual patient data meta-analysis. Gastroenterology (2005) 2.07
Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol (2011) 2.04
Asia-Pacific consensus guidelines on gastric cancer prevention. J Gastroenterol Hepatol (2008) 2.02
Proton pump inhibitors versus histamine 2 receptor antagonists for stress ulcer prophylaxis in critically ill patients: a systematic review and meta-analysis. Crit Care Med (2013) 2.01
Measuring patient preferences for colorectal cancer screening using a choice-format survey. Value Health (2007) 1.86
EUS: a meta-analysis of test performance in suspected choledocholithiasis. Gastrointest Endosc (2008) 1.85
Fecal transplant via retention enema for refractory or recurrent Clostridium difficile infection. Arch Intern Med (2012) 1.80
Ulcerative colitis. BMJ (2013) 1.76
Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis. Clin Gastroenterol Hepatol (2009) 1.67
Efficacy of 5-aminosalicylates in Crohn's disease: systematic review and meta-analysis. Am J Gastroenterol (2011) 1.60
Symptom-based outcome measures for dyspepsia and GERD trials: a systematic review. Am J Gastroenterol (2005) 1.59
Prevalence of uninvestigated dyspepsia 8 years after a large waterborne outbreak of bacterial dysentery: a cohort study. Gastroenterology (2010) 1.58
Helicobacter pylori eradication for the prevention of gastric neoplasia. Cochrane Database Syst Rev (2015) 1.58
Medical treatments in the short term management of reflux oesophagitis. Cochrane Database Syst Rev (2007) 1.57
Re: Cost-effectiveness of aspirin chemoprevention for Barrett's esophagus. J Natl Cancer Inst (2004) 1.54
Yield of diagnostic tests for celiac disease in individuals with symptoms suggestive of irritable bowel syndrome: systematic review and meta-analysis. Arch Intern Med (2009) 1.53
Common variants at the MHC locus and at chromosome 16q24.1 predispose to Barrett's esophagus. Nat Genet (2012) 1.52
5-aminosalicylates prevent relapse of Crohn's disease after surgically induced remission: systematic review and meta-analysis. Am J Gastroenterol (2010) 1.50
Inconsistent definitions for intention-to-treat in relation to missing outcome data: systematic review of the methods literature. PLoS One (2012) 1.48
Eradication therapy in Helicobacter pylori positive peptic ulcer disease: systematic review and economic analysis. Am J Gastroenterol (2004) 1.47
Irritable bowel syndrome: a 10-yr natural history of symptoms and factors that influence consultation behavior. Am J Gastroenterol (2008) 1.44
An evidence-based systematic review on medical therapies for inflammatory bowel disease. Am J Gastroenterol (2011) 1.42
Helicobacter pylori infection in functional dyspepsia. Nat Rev Gastroenterol Hepatol (2013) 1.41
Helicobacter pylori eradication has the potential to prevent gastric cancer: a state-of-the-art critique. Am J Gastroenterol (2005) 1.40
Acid-suppressive therapy with esomeprazole for relief of unexplained chest pain in primary care: a randomized, double-blind, placebo-controlled trial. Am J Gastroenterol (2012) 1.40
Management of inflammatory bowel disease with vitamin D: beyond bone health. J Crohns Colitis (2011) 1.40
Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol (2009) 1.39
Functional gastrointestinal disorders and mood disorders in patients with inactive inflammatory bowel disease: prevalence and impact on health. Inflamm Bowel Dis (2006) 1.38
Esophageal adenocarcinoma arising from Barrett's metaplasia has regional variations in the west. Gastroenterology (2002) 1.36
Treatment of hospitalized adult patients with severe ulcerative colitis: Toronto consensus statements. Am J Gastroenterol (2011) 1.29
Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability. Am J Gastroenterol (2009) 1.29
Ethnicity, gender, and socioeconomic status as risk factors for esophagitis and Barrett's esophagus. Am J Epidemiol (2005) 1.28
How do physician assessments of patient preferences for colorectal cancer screening tests differ from actual preferences? A comparison in Canada and the United States using a stated-choice survey. Health Econ (2009) 1.27
Efficacy of immunosuppressive therapy for inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol (2011) 1.24
Canadian Helicobacter Study Group Consensus Conference: Update on the approach to Helicobacter pylori infection in children and adolescents--an evidence-based evaluation. Can J Gastroenterol (2005) 1.17
Systematic review and meta-analysis of the prevalence of irritable bowel syndrome in individuals with dyspepsia. Clin Gastroenterol Hepatol (2009) 1.16
Post-infectious irritable bowel syndrome. World J Gastroenterol (2009) 1.15
Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol (2011) 1.14
How can the current strategies for Helicobacter pylori eradication therapy be improved? Can J Gastroenterol (2003) 1.12
Who consults with dyspepsia? Results from a longitudinal 10-yr follow-up study. Am J Gastroenterol (2007) 1.11
CD23-mediated IgE transport across human intestinal epithelium: inhibition by blocking sites of translation or binding. Gastroenterology (2005) 1.10
Functional Dyspepsia Treatment Trial (FDTT): a double-blind, randomized, placebo-controlled trial of antidepressants in functional dyspepsia, evaluating symptoms, psychopathology, pathophysiology and pharmacogenetics. Contemp Clin Trials (2012) 1.10
Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol (2011) 1.10
What is the prevalence of clinically significant endoscopic findings in subjects with dyspepsia? Systematic review and meta-analysis. Clin Gastroenterol Hepatol (2010) 1.10
Initial poor quality of life and new onset of dyspepsia: results from a longitudinal 10-year follow-up study. Gut (2006) 1.08
Recommendations on chronic constipation (including constipation associated with irritable bowel syndrome) treatment. Can J Gastroenterol (2007) 1.07
Fecal occult blood testing as a diagnostic test in symptomatic patients is not useful: a retrospective chart review. Can J Gastroenterol Hepatol (2014) 1.06
Rates of upper gastrointestinal endoscopy and gastro-oesophageal malignancy outcomes. Gut (2013) 1.05
Gastric Cancer Consensus conference recommends Helicobacter pylori screening and treatment in asymptomatic persons from high-risk populations to prevent gastric cancer. Am J Gastroenterol (2008) 1.04
Management of patients with nonvariceal upper gastrointestinal bleeding. Clin Gastroenterol Hepatol (2011) 1.03
Long-term health sequelae following E. coli and campylobacter contamination of municipal water. Population sampling and assessing non-participation biases. Can J Public Health (2005) 1.03
A community screening program for Helicobacter pylori saves money: 10-year follow-up of a randomized controlled trial. Gastroenterology (2005) 1.02
Effect of dyspepsia on survival: a longitudinal 10-year follow-up study. Am J Gastroenterol (2012) 1.02
Peripheral mechanisms in irritable bowel syndrome. N Engl J Med (2013) 1.01
14 day endoscopy study comparing risedronate and alendronate in postmenopausal women stratified by Helicobacter pylori status. J Rheumatol (2002) 1.00
An outbreak of acute bacterial gastroenteritis is associated with an increased incidence of irritable bowel syndrome in children. Am J Gastroenterol (2010) 0.97
The incidence of irritable bowel syndrome among community subjects with previous acute enteric infection. Dig Dis Sci (2006) 0.97
Adherence to guidelines for surveillance colonoscopy in patients with ulcerative colitis at a Canadian quaternary care hospital. Can J Gastroenterol (2009) 0.97
Adverse events with bismuth salts for Helicobacter pylori eradication: systematic review and meta-analysis. World J Gastroenterol (2008) 0.97
Once-daily dosing vs. conventional dosing schedule of mesalamine and relapse of quiescent ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol (2011) 0.96
Editorial: Sequential therapy for eradication of Helicobacter pylori: a new guiding light or a false dawn? Am J Gastroenterol (2009) 0.95
Resource utilization for acute lower gastrointestinal hemorrhage: the Ontario GI bleed study. Can J Gastroenterol (2002) 0.94
Randomized controlled trial comparing telephone and mail follow-up for recruitment of participants into a clinical trial of colorectal cancer screening. Trials (2013) 0.93
Efficacy of oral vs. topical, or combined oral and topical 5-aminosalicylates, in Ulcerative Colitis: systematic review and meta-analysis. Am J Gastroenterol (2011) 0.93
Practice of gastroenterologists in treating flaring inflammatory bowel disease patients with clostridium difficile: antibiotics alone or combined antibiotics/immunomodulators? Inflamm Bowel Dis (2010) 0.93
Does long term aspirin prevent cancer? BMJ (2010) 0.91
Prevalence of organic disease at colonoscopy in patients with symptoms compatible with irritable bowel syndrome: cross-sectional survey. Scand J Gastroenterol (2015) 0.89
Stress ulcer prophylaxis in critically ill patients: review of the evidence. Pol Arch Med Wewn (2012) 0.89
A systematic review of psychological therapies for nonulcer dyspepsia. Am J Gastroenterol (2004) 0.89
Methodology for randomized trials of patients with nonvariceal upper gastrointestinal bleeding: recommendations from an international consensus conference. Am J Gastroenterol (2009) 0.89
An audit of influenza vaccination status in adults with inflammatory bowel disease. Can J Gastroenterol (2012) 0.87
Cost-utility of laparoscopic Nissen fundoplication versus proton pump inhibitors for chronic and controlled gastroesophageal reflux disease: a 3-year prospective randomized controlled trial and economic evaluation. Value Health (2011) 0.87
Effect of sibling number in the household and birth order on prevalence of Helicobacter pylori: a cross-sectional study. Int J Epidemiol (2007) 0.87